Laparoscopic resection combined with ablation for multiple colorectal liver metastases: a multicentre propensity-matched analysis
- PMID: 40801919
- DOI: 10.1007/s00464-025-12040-5
Laparoscopic resection combined with ablation for multiple colorectal liver metastases: a multicentre propensity-matched analysis
Abstract
Background: Laparoscopic resection is the standard treatment for resectable colorectal liver metastases (CRLM). While the safety profile using combined ablation and resection (CARe) to treat CRLM has been documented, its efficacy has not been compared with that of resection alone in the laparoscopic setting. The aim of this study was to compare the short- and long-term outcomes of laparoscopic CARe with those of laparoscopic resection alone for multiple CRLM.
Methods: Patients with multiple CRLM who underwent laparoscopic resection at three medical centres from 2018 to 2023 were included. Perioperative and oncological outcomes were compared between the two groups. Propensity score matching (PSM) was performed.
Results: Of the 218 included patients, 67 (30.7%) underwent laparoscopic CARe, and 151 (69.3%) underwent laparoscopic resection alone. After PSM, 49 matched pairs of patients were included for each group. The postoperative complication rate was similar between the two groups (P = 0.964). The median recurrence-free survival (RFS) (11.8 vs. 12.1 months, P = 0.759) and overall survival (OS) (not reached, P = 0.656) were not significantly different between the two groups. Multivariate analysis revealed that ≥ 4 CRLM [hazard ratio (HR) = 1.86, 95% confidence interval (CI) 1.09-3.15, P = 0.022] and synchronous metastases (HR = 2.00, 95% CI 1.21-3.31, P = 0.007) and was independently associated with RFS, whereas bilobar distribution (HR = 3.20, 95% CI 1.04-9.82, P = 0.042) was independently associated with OS. No statistically significant differences were observed in the timing of recurrence (P = 0.666), the site of recurrence (P = 0.279), or the treatment administered after recurrence (P = 0.641) between the two groups.
Conclusions: Laparoscopic CARe may be considered as a useful treatment strategy for multiple CRLM.
Keywords: Ablation; Colorectal liver metastases; Laparoscopy; Liver resection; Minimally invasive surgery.
© 2025. The Author(s).
Conflict of interest statement
Declarations. Disclosures: Huachuan Song, Zhipeng Li, Shenyu Zhang, Xinyu Ling, Long Chen, Yongshuai Wang, Feng Zhang, Ruipeng Song, Fanzheng Meng, Lianxin Liu, Zehua Wu, Bing Han, and Jizhou Wang have no conflicts of interest to disclose.
Similar articles
-
Laparoscopic versus open liver resection for colorectal liver metastases: A systematic review and meta-analysis of studies with propensity score-based analysis.Int J Surg. 2017 Aug;44:191-203. doi: 10.1016/j.ijsu.2017.05.073. Epub 2017 Jun 2. Int J Surg. 2017. PMID: 28583897
-
Thermal ablation versus surgical resection of small-size colorectal liver metastases (COLLISION): an international, randomised, controlled, phase 3 non-inferiority trial.Lancet Oncol. 2025 Feb;26(2):187-199. doi: 10.1016/S1470-2045(24)00660-0. Epub 2025 Jan 20. Lancet Oncol. 2025. PMID: 39848272 Clinical Trial.
-
Minimally invasive hepatectomy vs. thermoablation for single small (≤3 cm) hepatocellular carcinoma: A weighted real-life national comparison.JHEP Rep. 2025 Apr 25;7(8):101420. doi: 10.1016/j.jhepr.2025.101420. eCollection 2025 Aug. JHEP Rep. 2025. PMID: 40689143 Free PMC article.
-
Comparative outcomes of combined thermal ablation and liver resection versus liver resection alone for multiple colorectal liver metastases: a systematic review and meta-analysis.Front Oncol. 2025 Jun 27;15:1613615. doi: 10.3389/fonc.2025.1613615. eCollection 2025. Front Oncol. 2025. PMID: 40657243 Free PMC article.
-
Comparison of Two Modern Survival Prediction Tools, SORG-MLA and METSSS, in Patients With Symptomatic Long-bone Metastases Who Underwent Local Treatment With Surgery Followed by Radiotherapy and With Radiotherapy Alone.Clin Orthop Relat Res. 2024 Dec 1;482(12):2193-2208. doi: 10.1097/CORR.0000000000003185. Epub 2024 Jul 23. Clin Orthop Relat Res. 2024. PMID: 39051924
References
-
- Bray F, Laversanne M, Sung H et al (2024) Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 74(3):229–263. https://doi.org/10.3322/caac.21834 - DOI - PubMed
-
- Cervantes A, Adam R, Roselló S et al (2023) Metastatic colorectal cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol 34(1):10–32. https://doi.org/10.1016/j.annonc.2022.10.003 - DOI - PubMed
-
- Siegel RL, Wagle NS, Cercek A, Smith RA, Jemal A (2023) Colorectal cancer statistics, 2023. CA Cancer J Clin 73(3):233–254. https://doi.org/10.3322/caac.21772 - DOI - PubMed
-
- Creasy JM, Sadot E, Koerkamp BG et al (2018) Actual 10-year survival after hepatic resection of colorectal liver metastases: what factors preclude cure? Surgery 163(6):1238–1244. https://doi.org/10.1016/j.surg.2018.01.004 - DOI - PubMed
-
- Ratti F, Cipriani F, Fiorentini G et al (2021) Evolution of surgical treatment of colorectal liver metastases in the real world: single center experience in 1212 cases. Cancers 13(5):1178. https://doi.org/10.3390/cancers13051178 - DOI - PubMed - PMC
Grants and funding
- 82170618/National Natural Science Foundation of China
- 202204295107020019/Anhui Provincial Key Research and Development Plan
- 2024AH020016/Anhui University Outstanding Youth Research Project
- 2023IHM01020/Research Institute of Pioneer Medicine and Frontier Technology, Hefei Comprehensive National Science Center
LinkOut - more resources
Full Text Sources
Miscellaneous